OVERVIEW
OUR EQUITY STORY
UCB FINANCIALS
UCB GOVERNANCE
OUR SHAREHOLDERS
ESG OVERVIEW
DOWNLOAD CENTER
NEWS
UCB STORIES
CONTACT
SETTINGS
UCB.COM
SHARE APP
Share information
252.00 €
+0.28 %
27/03/2026 17:38
Open
High
Low
Volume
252.80 €
254.80 €
245.20 €
292,979
Latest News
27-Mar-2026
UCB announces new BIMZELX[®] (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa
27-Mar-2026
UCB presents new BIMZELX[®] (bimekizumab-bkzx) data at AAD demonstrating high rates of durable and complete skin clearance in moderate-to-severe plaque psoriasis
27-Mar-2026
Acquisition of own shares
27-Mar-2026
UCB Annual General Meeting of Shareholders 2026
Interim reports
26-Feb-2026
2025 full-year result
31-Jul-2025
2025 half-year results
27-Feb-2025
2024 full-year results
UCB Stories
26-Feb-2026
Strong execution in service of patients and sustainable value
31-Jul-2025
Stronger every semester - From differentiated innovation to outstanding delivery
26-Feb-2025
Strong launch execution driving company growth
In Focus
26-Feb-2026 Full Year Results 2025